長藥控股(300391.SZ):預計2024年虧損5億元-7.5億元
格隆匯1月23日丨長藥控股(300391.SZ)公佈,預計2024年虧損75,000萬元–50,000萬元,扣非虧損72,000萬元–48,000萬元,營業收入11,000萬元–15,000萬元,歸屬於上市公司股東的所有者權益-55,000萬元–-37,000萬元。1、2024年公司因欠繳税款部分子公司開具發票受限,業務開展緩慢,公司資金緊張,導致公司營業收入、毛利率下滑明顯,同比下降幅度較大。2、本年度公司計提資產減值損失、信用減值損失預計6.73億元左右。其中,商譽減值損失預計2.36億元左右,應收賬款壞賬準備預計4億元左右。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.